Generic Name: bleomycin (BLEE oh MYE sin)Brand Names: Blenoxane
Bleomycin is a cancer medication. Bleomycin interferes with the growth of cancer cells and slows their growth and spread in the body.
Bleomycin is used to treat squamous cell carcinoma, a skin cancer that can affect the mouth, throat, nose and sinuses, penis, vagina, cervix, and other. Bleomycin is also used to treat Hodgkin's disease and non-Hodgkin's lymphoma, testicular cancer, and malignant pleural effusion (a build-up of fluid in the outer tissues of the lungs, caused by certain types of cancer).
Bleomycin may also be used for other purposes not listed in this medication guide.
Before receiving bleomycin, tell your doctor if you have lung disease or a breathing disorder, kidney disease, or liver disease.
To be sure this medication is not causing harmful effects on your lungs, you may need to have chest X-rays or other lung function tests on a regular basis. Do not miss any follow-up visits to your doctor for X-rays or other tests. If you need to have any type of surgery, tell the surgeon ahead of time that you are being treated with bleomycin. Call your doctor at once if you have a serious side effect such as fever, chills, mouth sores, confusion, weakness, loss of appetite, rapid weight loss, sudden chest pain or discomfort, wheezing, dry cough, feeling short of breath, feeling like you might pass out, unusual hardening or thickening of your skin. or severe skin reaction (redness, itching, rash, blistering, or tenderness).If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before receiving bleomycin, tell your doctor if you have:
lung disease or a breathing disorder;
Bleomycin is given as an injection through a needle placed into a vein or muscle, or as a shot given under the skin When treating pleural effusion, bleomycin is given through a chest tube. You will receive this injection in a clinic or hospital setting.
Bleomycin is usually given once or twice per week, depending on the condition being treated. Follow your doctor's instructions.
To be sure this medication is not causing harmful effects on your lungs, you may need to have chest X-rays or other lung function tests on a regular basis. Do not miss any follow-up visits to your doctor for X-rays or other tests. If you need to have any type of surgery, tell the surgeon ahead of time that you are being treated with bleomycin.Call your doctor for instructions if you miss an appointment for your bleomycin injection.
Since bleomycin is given in a clinical setting by a healthcare professional, an overdose of this medication is not likely to occur.
Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are being treated with bleomycin.
fever or chills;
sudden chest pain or discomfort, wheezing, dry cough or hack;
feeling short of breath on exertion;
chest discomfort, wheezing, dry cough or hack;
confusion, feeling weak or tired, loss of appetite, rapid weight loss;
feeling like you might pass out;
white patches or sores inside your mouth or on your lips;
severe redness, itching, rash, blistering, or tenderness of your skin; or
unusual hardening or thickening of your skin.
Less serious side effects may include:
dark streaks or discoloring on your skin;
fingernail or toenail changes;
temporary hair loss;
mild itching;
vomiting;
pain near your tumor; or
redness, warmth, itching, or swelling around the IV needle.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Squamous Cell Carcinoma:
0.25 to 0.50 units/kg (10 to 20 units/m2) intravenously, intramuscularly, or subcutaneously weekly or twice weekly.Squamous cell carcinoma sometimes requires as long as 3 weeks before any improvement is noted.
Usual Adult Dose for non-Hodgkin's Lymphoma:
Because of the possibility of an anaphylactic reaction, the manufacturer recommends that lymphoma patients be treated with two units or less for the first two doses. However, there is at least one known case of fatal hyperpyrexia in a patient without lymphoma following an initial dose of 7.5 units. Test doses are controversial in non-lymphoma patients.Following a 1 unit test dose, the patient should be observed for a reaction for one to two hours if the dose is administered intravenously or two to four hours if the dose is administered intramuscularly. If no acute reaction occurs, then the regular dosage schedule may be followed.0.25 to 0.50 units/kg (10 to 20 units/m2) intravenously, intramuscularly, or subcutaneously weekly or twice weekly.
Usual Adult Dose for Testicular Cancer:
0.25 to 0.50 units/kg (10 to 20 units/m2) intravenously, intramuscularly, or subcutaneously weekly or twice weekly.Improvement in testicular tumors is prompt and noted within 2 weeks. If no improvement is seen at this time, improvement is unlikely.
Usual Adult Dose for Hodgkin's Disease:
Because of the possibility of an anaphylactic reaction, the manufacturer recommends that lymphoma patients be treated with two units or less for the first two doses. However, there is at least one known case of fatal hyperpyrexia in a patient without lymphoma following an initial dose of 7.5 units. Test doses are controversial in non-lymphoma patients.Following a 1 unit test dose, the patient should be observed for a reaction for one to two hours if the dose is administered intravenously or two to four hours if the dose is administered intramuscularly. If no acute reaction occurs, then the regular dosage schedule may be followed.0.25 to 0.50 units/kg (10 to 20 units/m2) intravenously, intramuscularly, or subcutaneously weekly or twice weekly.After a 50% response, a maintenance dose of 1 unit daily or 5 units weekly intravenously or intramuscularly should be given.Improvement in Hodgkin's Disease is prompt and noted within 2 weeks. If no improvement is seen at this time, improvement is unlikely.
Usual Adult Dose for Malignant Pleural Effusion:
60 units administered as a single bolus intrapleural injection.
Usual Pediatric Dose for Squamous Cell Carcinoma:
0.25 to 0.50 units/kg (10 to 20 units/m2) intravenously, intramuscularly, or subcutaneously weekly or twice weekly.Squamous cell carcinoma sometimes requires as long as 3 weeks before any improvement is noted.
Usual Pediatric Dose for non-Hodgkin's Lymphoma:
Because of the possibility of an anaphylactic reaction, the manufacturer recommends that lymphoma patients be treated with two units or less for the first two doses. However, there is at least one known case of fatal hyperpyrexia in a patient without lymphoma following an initial dose of 7.5 units. Test doses are controversial in non-lymphoma patients.Following a 1 unit test dose, the patient should be observed for a reaction for one to two hours if the dose is administered intravenously or two to four hours if the dose is administered intramuscularly. If no acute reaction occurs, then the regular dosage schedule may be followed.0.25 to 0.50 units/kg (10 to 20 units/m2) intravenously, intramuscularly, or subcutaneously weekly or twice weekly.
Usual Pediatric Dose for Testicular Cancer:
0.25 to 0.50 units/kg (10 to 20 units/m2) intravenously, intramuscularly, or subcutaneously weekly or twice weekly.Improvement in testicular tumors is prompt and noted within 2 weeks. If no improvement is seen at this time, improvement is unlikely.
Usual Pediatric Dose for Hodgkin's Disease:
Because of the possibility of an anaphylactic reaction, the manufacturer recommends that lymphoma patients be treated with two units or less for the first two doses. However, there is at least one known case of fatal hyperpyrexia in a patient without lymphoma following an initial dose of 7.5 units. Test doses are controversial in non-lymphoma patients.Following a 1 unit test dose, the patient should be observed for a reaction for one to two hours if the dose is administered intravenously or two to four hours if the dose is administered intramuscularly. If no acute reaction occurs, then the regular dosage schedule may be followed.0.25 to 0.50 units/kg (10 to 20 units/m2) intravenously, intramuscularly, or subcutaneously weekly or twice weekly.After a 50% response, a maintenance dose of 1 unit daily or 5 units weekly intravenously or intramuscularly should be given.Improvement in Hodgkin's Disease is prompt and noted within 2 weeks. If no improvement is seen at this time, improvement is unlikely.
Usual Pediatric Dose for Malignant Pleural Effusion:
60 units administered as a single bolus intrapleural injection.
Tell your doctor about all other cancer treatments you are receiving.
There may be other drugs that can interact with bleomycin. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.